AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 365123 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 29
Study 365123 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 29
Study 365123 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 29
Study 365123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 365123 — intervention group
Group type: EXPERIMENTAL
Intervention: All three drugs (Methylphenidate, Dextroamphetamine, Caffeine)
Number of subjects: 29
Study 31645004 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based training on epilepsy
Number of subjects: 72
Study 31645004 — intervention group
Group type: COMPARATOR
Intervention: Standard child mannequin training on epilepsy
Number of subjects: 72
Study 28663228 — intervention group
Group type: EXPERIMENTAL
Intervention: NADT with leuprolide acetate plus abiraterone acetate and prednisone
Number of subjects: 0
Study 28663228 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide acetate alone
Number of subjects: 0
Study 25937024 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week non-surgical treatment program (individualized progressed neuromuscular exercise, patient education, insoles, dietary advice, prescription of pain medication if indicated)
Number of subjects: 100
Study 25937024 — intervention group
Group type: COMPARATOR
Intervention: Usual care (two leaflets with information and advice on knee OA and recommended treatments)
Number of subjects: 100
Study 23570296 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic full-coverage CAD-CAM crown (Group 1)
Number of subjects: 48
Study 23570296 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic full-coverage CAD-CAM crown (Group 2)
Number of subjects: 48
Study 23570296 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite full-coverage CAD-CAM crown (LPCpr, Group 3)
Number of subjects: 48
Study 23570296 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite full-coverage CAD-CAM crown (SPCpr, Group 4)
Number of subjects: 48
Study 23570296 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic CEREC machined endocrown (EndoCer, Group 5)
Number of subjects: 48
Study 23570296 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite CEREC machined endocrown (EndoCpr, Group 6)
Number of subjects: 48
Study 23570296 — intervention group
Group type: COMPARATOR
Intervention: All groups (LPCpr, SPCpr, EndoCpr)
Number of subjects: 48
Study 23570296 — intervention group
Group type: COMPARATOR
Intervention: Different post lengths
Number of subjects: 48
Study 22087850 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive implementation program for pharmacy project assistants
Number of subjects: 862
Study 22087850 — intervention group
Group type: COMPARATOR
Intervention: Control group (written manual on EAFD and EASD implementation)
Number of subjects: 862
Study 22087850 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive implementation program
Number of subjects: 862
Study 22087850 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 862
Study 18946878 — intervention group
Group type: EXPERIMENTAL
Intervention: P filter
Number of subjects: 67
Study 18946878 — intervention group
Group type: COMPARATOR
Intervention: POV filter
Number of subjects: 67
Study 18946878 — intervention group
Group type: COMPARATOR
Intervention: POVF filter
Number of subjects: 67
Study 18946878 — intervention group
Group type: EXPERIMENTAL
Intervention: All filters
Number of subjects: 67
Study 18946878 — intervention group
Group type: EXPERIMENTAL
Intervention: POV and POVF filters
Number of subjects: 67
Study 17135805 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based assessments using experimental instruments
Number of subjects: 644
Study 17135805 — intervention group
Group type: COMPARATOR
Intervention: Clinic-based assessments during clinic visits
Number of subjects: 644
Study 14592563 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 10224982 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepartum and postpartum relapse prevention
Number of subjects: 0
Study 10224982 — intervention group
Group type: COMPARATOR
Intervention: Prepartum relapse prevention
Number of subjects: 0
Study 10224982 — intervention group
Group type: COMPARATOR
Intervention: Self-help booklet only
Number of subjects: 0
Study 8732377 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase with subcutaneous heparin
Number of subjects: 553
Study 8732377 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase with intravenous heparin
Number of subjects: 553
Study 8732377 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator with intravenous heparin
Number of subjects: 553
Study 8732377 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase plus tissue plasminogen activator with intravenous heparin
Number of subjects: 553
Study 2008949 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg midazolam
Number of subjects: 100
Study 2008949 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg midazolam
Number of subjects: 100
Study 2008949 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg midazolam
Number of subjects: 100
Study 2008949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 2008949 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (1, 2, or 3 mg)
Number of subjects: 100
Study 2008949 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (3 mg)
Number of subjects: 100
Study 7043494 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 intravenously
Number of subjects: 22
Study 7043494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 7043494 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1
Number of subjects: 22
Study 31871250 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy without drain
Number of subjects: 50
Study 31871250 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy with drain
Number of subjects: 50
Study 31118157 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline blood IL-6
Number of subjects: 726
Study 31118157 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline leptin
Number of subjects: 726
Study 31118157 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CRP
Number of subjects: 726
Study 29100702 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS)
Number of subjects: 2008
Study 29100702 — intervention group
Group type: COMPARATOR
Intervention: Cobalt-chromium everolimus-eluting stents (EES)
Number of subjects: 2008
Study 29100702 — intervention group
Group type: EXPERIMENTAL
Intervention: BVS
Number of subjects: 2008
Study 29100702 — intervention group
Group type: COMPARATOR
Intervention: EES
Number of subjects: 2008
Study 26383577 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental health instruction before treatment
Number of subjects: 154
Study 26383577 — intervention group
Group type: COMPARATOR
Intervention: Regular treatment (Control)
Number of subjects: 154
Study 23281216 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic umbilical cord blood (UCB) potentiated with recombinant human erythropoietin (rhEPO)
Number of subjects: 96
Study 23281216 — intervention group
Group type: COMPARATOR
Intervention: Recombinant human erythropoietin (rhEPO) and placebo UCB
Number of subjects: 96
Study 23281216 — intervention group
Group type: COMPARATOR
Intervention: Placebo UCB and placebo rhEPO
Number of subjects: 96
Study 20851046 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 23
Study 20851046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 18648258 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D‐FLASH sequence
Number of subjects: 34
Study 18648258 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D‐VIBE sequence
Number of subjects: 34
Study 18648258 — intervention group
Group type: COMPARATOR
Intervention: Comparison of image quality between 3D‐FLASH and 3D‐VIBE
Number of subjects: 34
Study 17137977 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecnis ZM001 IOL (AMO) (Group 2)
Number of subjects: 60
Study 17137977 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof ReSTOR SA60D3 IOL (Alcon) (Group 3)
Number of subjects: 60
Study 17137977 — intervention group
Group type: EXPERIMENTAL
Intervention: SA40N IOL (AMO) (Group 1)
Number of subjects: 60
Study 12518130 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnifying colonoscopy
Number of subjects: 660
Study 12518130 — intervention group
Group type: COMPARATOR
Intervention: Nonmagnifying colonoscopy
Number of subjects: 660
Study 10685653 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent biochemotherapy with cisplatin, vinblastine, and dacarbazine (CVD) plus IL-2 and IFN-alpha
Number of subjects: 1000
Study 10685653 — intervention group
Group type: COMPARATOR
Intervention: CVD alone
Number of subjects: 1000
Study 9590590 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimexolone 1%
Number of subjects: 182
Study 9590590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 7512679 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer solution without antihistamines
Number of subjects: 240
Study 7512679 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemaccel without antihistamines
Number of subjects: 240
Study 7512679 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihistamines (dimetindene plus cimetidine)
Number of subjects: 240
Study 7512679 — intervention group
Group type: COMPARATOR
Intervention: Overall
Number of subjects: 240
Study 3343463 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential pulse defibrillation with four small mesh electrodes (6 cm2)
Number of subjects: 21
Study 3343463 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential pulse defibrillation with two small (6 cm2) and two large (13 cm2) mesh electrodes
Number of subjects: 21
Study 3343463 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential pulse defibrillation with four large mesh electrodes (13 cm2)
Number of subjects: 21
Study 3343463 — intervention group
Group type: COMPARATOR
Intervention: Single pulse defibrillation with four small mesh electrodes (6 cm2)
Number of subjects: 21
Study 31950265 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-group (image-free handheld robotic sculpting system)
Number of subjects: 77
Study 31950265 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional alignment with intramedullary rods)
Number of subjects: 77
Study 31950265 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-group
Number of subjects: 77
Study 31950265 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study 30074872 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 29
Study 30074872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 27088609 — intervention group
Group type: EXPERIMENTAL
Intervention: Hologram bracelet (n = 68)
Number of subjects: 175
Study 27088609 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 53)
Number of subjects: 175
Study 27088609 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 54)
Number of subjects: 175
Study 25802309 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine
Number of subjects: 50
Study 25802309 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine administered to vaccine-naive children
Number of subjects: 50
Study 23810742 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) meloxicam (0.2mg/kg)
Number of subjects: 24
Study 23810742 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal insufflation of ozone (10 mL of 30 μg/mL)
Number of subjects: 24
Study 23810742 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint injection of ozone (0.5 mL of 30 μg/mL)
Number of subjects: 24
Study 20656157 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavefront-guided photorefractive keratectomy (PRK)
Number of subjects: 203
Study 20656157 — intervention group
Group type: COMPARATOR
Intervention: Wavefront-guided laser in situ keratomileusis (LASIK)
Number of subjects: 203
Study 18385498 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream, applied twice weekly for 16 weeks
Number of subjects: 52
Study 18385498 — intervention group
Group type: COMPARATOR
Intervention: Placebo, applied twice weekly for 16 weeks
Number of subjects: 52
Study 18385498 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 52
Study 18385498 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream and Placebo
Number of subjects: 52
Study 16369855 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-emptive antibiotic treatment with ceftriaxone
Number of subjects: 20
Study 16369855 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 20
Study 12399736 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfine (PDT)
Number of subjects: 609
Study 12399736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 609
Study 10211086 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF (400 mg/m2 cyclophosphamide, 25 mg/m2 doxorubicin, 500 mg/m2 5-fluorouracil)
Number of subjects: 415
Study 10211086 — intervention group
Group type: COMPARATOR
Intervention: CMF (40 mg/m2 methotrexate, cyclophosphamide, 5-fluorouracil)
Number of subjects: 415
Study 8775024 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic manipulation for tension-type headaches
Number of subjects: 729
Study 8775024 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic manipulation for migraine headaches
Number of subjects: 729
Study 8775024 — intervention group
Group type: COMPARATOR
Intervention: No treatment, some types of mobilization and ice, amitriptyline (as control for tension-type headaches)
Number of subjects: 729
Study 2169216 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard heparin, 5000 units subcutaneously three times a day
Number of subjects: 41
Study 2169216 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparin 3500 anti-Xa units subcutaneously once daily
Number of subjects: 41
Study 670535 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Interview
Number of subjects: 0
Study 670535 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity Survey
Number of subjects: 0
Study 670535 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity Survey (scored by California scoring key)
Number of subjects: 0
Study 670535 — intervention group
Group type: COMPARATOR
Intervention: Comparison with North America
Number of subjects: 0
Study 6818583 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 15
Study 6818583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30561825 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact
Number of subjects: 35
Study 30561825 — intervention group
Group type: COMPARATOR
Intervention: Standard care with supportive positioning by parents
Number of subjects: 35
Study 28370327 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mL of 2% lidocaine with 1:80,000 epinephrine
Number of subjects: 97
Study 28370327 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mL of 2% lidocaine with 1:80,000 epinephrine
Number of subjects: 97
Study 28370327 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate changes
Number of subjects: 97
Study 27678425 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (IT) with lovastatin (40 mg/d), niacin (2.5 g/d), and colestipol (20 g/d) from 1989 to 2004, followed by double therapy with simvastatin (40–80 mg/d) and niacin from 2005 to 2006 and triple therapy of ezetimibe 10 mg and simvastatin 40 to 80 mg/d plus niacin during 2007 to 2012
Number of subjects: 175
Study 27678425 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 175
Study 24338597 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-adapted physical exercises (10 sessions)
Number of subjects: 60
Study 24338597 — intervention group
Group type: COMPARATOR
Intervention: Instructional booklet (control)
Number of subjects: 60
Study 22066583 — intervention group
Group type: EXPERIMENTAL
Intervention: Δ9-tetrahydrocannabinol (THC) inhalation
Number of subjects: 13
Study 22066583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 19890242 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimebon
Number of subjects: 0
Study 19890242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17466850 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified anterior edge IOL
Number of subjects: 84
Study 17466850 — intervention group
Group type: COMPARATOR
Intervention: Sharp anterior edge IOL
Number of subjects: 84
Study 17466850 — intervention group
Group type: COMPARATOR
Intervention: Comparison of modified edge IOL and sharp edge IOL
Number of subjects: 84
Study 16351768 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight potato varieties (GI values from 56 to 94)
Number of subjects: 17
Study 16351768 — intervention group
Group type: COMPARATOR
Intervention: Glucose standard (control)
Number of subjects: 17
Study 11901288 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% brimonidine
Number of subjects: 20
Study 11901288 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% apraclonidine
Number of subjects: 20
Study 11901288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10855330 — intervention group
Group type: COMPARATOR
Intervention: Plaster immobilization for three weeks followed by rehabilitation (Group I)
Number of subjects: 50
Study 10855330 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization (Group II)
Number of subjects: 50
Study 10155349 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg once daily)
Number of subjects: 140
Study 10155349 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (100 mg once daily)
Number of subjects: 140
Study 10155349 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 140
Study 10155349 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 140
Study 2369292 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised training program for 12 weeks after an initial 8-week program
Number of subjects: 0
Study 2369292 — intervention group
Group type: COMPARATOR
Intervention: Discharged after initial program with written instructions for home exercise
Number of subjects: 0
Study 717750 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane inhalation anaesthesia
Number of subjects: 30
Study 31818687 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group A (early mobilization protocol: sat up on day 2, off-bed activity on day 3)
Number of subjects: 149
Study 31818687 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group B (early mobilization protocol: sat up on day 2, off-bed activity on day 3)
Number of subjects: 149
Study 31818687 — intervention group
Group type: COMPARATOR
Intervention: Control group A (standard protocol: sat up on day 4, off-bed activity on day 6)
Number of subjects: 149
Study 31818687 — intervention group
Group type: COMPARATOR
Intervention: Control group B (standard protocol: sat up on day 4, off-bed activity on day 6)
Number of subjects: 149
Study 31818687 — intervention group
Group type: EXPERIMENTAL
Intervention: Test groups (A and B)
Number of subjects: 149
Study 31354147 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic left anterior transperitoneal submesocolic adrenalectomy (LLATSA)
Number of subjects: 34
Study 29316908 — intervention group
Group type: EXPERIMENTAL
Intervention: Curamin® (500 mg capsules containing 350 mg curcuminoids and 150 mg boswellic acid)
Number of subjects: 201
Study 29316908 — intervention group
Group type: EXPERIMENTAL
Intervention: CuraMed® (500 mg capsules containing 333 mg curcuminoids)
Number of subjects: 201
Study 29316908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 25721053 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience Corps (EC) program
Number of subjects: 0
Study 25721053 — intervention group
Group type: COMPARATOR
Intervention: Usual volunteer opportunities (Control)
Number of subjects: 0
Study 23770843 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil‐based intravenous fat emulsion (FIFE) at 1 g/kg/d
Number of subjects: 19
Study 23770843 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil‐based intravenous fat emulsion (SIFE)
Number of subjects: 19
Study 21998076 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone 12 mg
Number of subjects: 33
Study 21998076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 18608562 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibruline Instant (20 g/day)
Number of subjects: 84
Study 18608562 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrulose F97
Number of subjects: 84
Study 18608562 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibruline Instant
Number of subjects: 84
Study 18608562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 17256759 — intervention group
Group type: EXPERIMENTAL
Intervention: Licartin (15.4 MBq/kg)
Number of subjects: 60
Study 17256759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 17256759 — intervention group
Group type: EXPERIMENTAL
Intervention: Licartin
Number of subjects: 60
Study 15889656 — intervention group
Group type: EXPERIMENTAL
Intervention: Bar-clip attachments
Number of subjects: 18
Study 15889656 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball-socket attachments
Number of subjects: 18
Study 15889656 — intervention group
Group type: COMPARATOR
Intervention: Magnet attachments
Number of subjects: 18
Study 15889656 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS score
Number of subjects: 18
Study 15889656 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum bite force
Number of subjects: 18
Study 12017521 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation programme based on the guidelines of the Dutch Heart Association (DHA)
Number of subjects: 40
Study 12017521 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (no intervention during waiting period)
Number of subjects: 40